RNAC vs. PDSB, SGMT, ACET, NVCT, SYRS, AMLX, SKYE, KPTI, DMAC, and RZLT
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include PDS Biotechnology (PDSB), Sagimet Biosciences (SGMT), Adicet Bio (ACET), Nuvectis Pharma (NVCT), Syros Pharmaceuticals (SYRS), Amylyx Pharmaceuticals (AMLX), Skye Bioscience (SKYE), Karyopharm Therapeutics (KPTI), DiaMedica Therapeutics (DMAC), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.
PDS Biotechnology received 52 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 67.42% of users gave PDS Biotechnology an outperform vote.
Cartesian Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 70.84%. PDS Biotechnology has a consensus target price of $17.33, suggesting a potential upside of 391.03%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Cartesian Therapeutics.
87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 31.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 10.0% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Cartesian Therapeutics had 5 more articles in the media than PDS Biotechnology. MarketBeat recorded 18 mentions for Cartesian Therapeutics and 13 mentions for PDS Biotechnology. Cartesian Therapeutics' average media sentiment score of 0.74 beat PDS Biotechnology's score of 0.65 indicating that Cartesian Therapeutics is being referred to more favorably in the media.
PDS Biotechnology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -983.93%. Cartesian Therapeutics' return on equity of -58.21% beat PDS Biotechnology's return on equity.
Cartesian Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
PDS Biotechnology has lower revenue, but higher earnings than Cartesian Therapeutics.
Summary
Cartesian Therapeutics beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
